Table 2:

Pharmacodynamic phenotype analyses data and results.

	Clopidogrel	ACE inhibitors	Statins	Vancomycin	Gentamicin	Tacrolimus	Cyclosporine
Subjects (n)	2,518	5,925	5,834	5,776	235	1,033	273
SNPs post-QC (n)	777,427	1,024,789	1,514,275	1,052,294	1,246,692	1,188,309	1,263,625
Female (n, (%))	583 (23.2)	2,685 (45.3)	2,083 (35.7)	2,461 (42.6)	115 (48.9)	383 (37.0)	121 (44.3)
Age (mean, (SD), years)	64.8 (11.2)	NA	NA	57.1 (15.5)	49.2 (17.9)	53.1 (11.8)	53.1 (12.8)
Phenotype studied	Standardized Platelet Reactivity	Cough	Major Adverse Cardiac Events	Peak Creatinine
Cases (n, (%))	-	1,326 (22.3)	1,708 (29.2)	-	-	-	-
Phenotype (median)	0.006	-	-	1.10	1.10	1.69	1.50
${\sigma }_g^2$	0.24	0.01	0.03	0.02	0.28	0.09	0.15
$h_{SNP}^2$	0.25 [0.00, 0.41]	0.05 [0.00, 0.15]	0.15 [0.00, 0.36]	0.07 [0.00,0.20]	0.43 [0.00, 0.93]	0.27 [0.00, 0.72]	0.52 [0.00, 0.92]
Large effect variant (prop., (# SNPs))	0.38 (46)	0.19 (50)	0.05 (22)	0.13 (36)	0.37 (53)	0.17 (44)	0.28 (41)
Moderate-effect variant (prop., (# SNPs))	0.33 (293)	0.46 (341)	0.33 (342)	0.46 (401)	0.27 (282)	0.50 (425)	0.32 (314)
Small-effect variant (prop., (# SNPs))	0.29 (2,453)	0.36 (2,902)	0.62 (4,992)	0.41 (3,211)	0.36 (2,930)	0.33 (2,467)	0.40 (3,528)

SD – Standard Deviation; C:D Ratio – Concentration to Dose Ratio; ${\sigma }_g^2$ – Additive Genetic Variance; $h_{SNP}^2$ - Narrow-sense Heritability, with conventionally calculated high density credible interval shown in brackets. Prop.: Proportion contributed to total $h_{SNP}^2$. NA indicates data not available.